Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting
June 09 2021 - 08:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, announced today it will present
real-world clinical data as part of the Clinical TMS Society
(CTMSS) Annual Meeting.
The CTMSS, a professional association that aims to optimize
awareness and accessibility of transcranial magnetic stimulation
(TMS), will hold its yearly meeting June 10-12 in West Palm Beach,
Florida. Neuronetics is a Platinum Sponsor of the event, during
which clinical research and advancements with NeuroStar Advanced
Therapy for Mental Health will be highlighted in two sponsored
presentations, two poster presentations, and three podium talks on
the following topics:
Sponsored Presentations
- Outcomes Registry Data – Overall Efficacy and
Comparison of Dash v. Standard (NeuroStar Partner Presentation and
Breakfast, Friday, June 11, 8:00 a.m. EDT, Exhibit Hall
B)
Data on clinical outcomes from the NeuroStar Outcomes Registry,
including comparative outcomes of Dash and Standard protocols and
the overall efficacy of NeuroStar for MDD patients, will be
presented by Harold A. Sackeim, PhD, Professor of Clinical
Psychology in Psychiatry and Radiology at the College of Physicians
and Surgeons, Columbia University.
- Outcomes Registry Data – Comparison of Left Side v.
Bilateral Treatment Outcomes (NeuroStar Partner Presentation and
Lunch, Saturday, June 12, 12:15 p.m. EDT, Exhibit Hall
B)
Specifics on the utilization of unilateral and bilateral
stimulation using data from the NeuroStar Outcomes Registry will be
presented by Harold A. Sackeim, PhD and Scott Aaronson, MD,
Director of Clinical Research Programs at Sheppard Pratt Health
System.
Poster Presentations (Friday, June 11, 5:30 p.m.-7:30
p.m. EDT, Exhibit Hall A)
- A Comparison of Left Unilateral TMS Treatment vs.
Sequential Bilateral Treatment in a Large Registry Cohort
will be presented by Harold A. Sackeim, PhD and Scott Aaronson,
MD.
- The Reintroduction of TMS as a Strategy for Maintenance
Treatment for Adolescents with Treatment Resistant
Depression will be presented by Paul Croarkin, DO.
Podium Talks
- The Evolving Evidence Base for TMS in Bipolar
Depression (Friday, June 11, 10:10 a.m. EDT,
Ballroom)
Data from an investigator-initiated trial (IIT) using NeuroStar
will be presented by Scott Aaronson, MD.
- Brain Stimulation Interventions for Mood Disorders:
Innovations and Future Directions (Saturday, June 12, 1:30 p.m.
EDT, Ballroom)
Insight on the future of brain stimulation, including TMS, will
be presented by Harold A. Sackeim, PhD.
- Recent Advances in TMS for Adolescents and Young Adults
(Saturday, June 12, 3 p.m. EDT, Ballroom)
An “outside the box” vision for future TMS therapy in
adolescents; discussion about reintroduction and maintenance of TMS
therapy; and information about clinical studies, including
Investigator-Initiated Trials (IIT), a Randomized Controlled Trial
(RCT), and a current NIMH study with Neuronetics equipment will be
presented by Paul Croarkin, DO.
“It’s an honor and exciting to present new findings at the
Clinical TMS Society Meeting, from the NeuroStar Outcomes
Registry, the largest depression registry in the world,” said
Harold A. Sackeim, PhD, Professor of Clinical Psychology in
Psychiatry and Radiology at the College of Physicians and Surgeons,
Columbia University, and presenter at the Clinical TMS Society
Annual Meeting. “I continue to be impressed with the remarkable
safety and efficacy of TMS for people suffering with major
depression. The findings from the Registry strongly support the
value of this intervention and will have substantial impact on how
TMS is practiced.”
In addition to these scientific presentations, Neuronetics will
participate in the PULSES Workshop, a two-day, hands-on training
course delivered by clinicians and researchers on June 9-10.
As an exhibitor during the meeting on June 10-12, Neuronetics
will offer attendees the opportunity to learn more about NeuroStar
Advanced Therapy for Mental Health, including the proprietary
5-STARS to Success Program for NeuroStar providers. Visit the
Clinical TMS Society’s website to learn more about the annual
meeting. Those interested in attending can register online
here.
With 4,000,000 NeuroStar treatment sessions delivered globally
and 900 practice locations in the U.S., Neuronetics continues to be
an industry leader in transcranial magnetic stimulation for
depression on their mission to renew lives by transforming
neurohealth. For more information,
visit www.neurostar.com.
About NeuroneticsNeuronetics,
Inc. is a commercial-stage medical technology company focused
on designing, developing, and marketing products that improve the
quality of life for patients who suffer from psychiatric disorders.
Its commercial product, the NeuroStar® Advanced Therapy System, is
a non-invasive and non-systemic office-based treatment that uses
transcranial magnetic stimulation, or TMS, to create a pulsed,
MRI-strength magnetic field that induces electrical currents
designed to stimulate specific areas of the brain associated with
mood. The system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. Visit NeuroStar.com for safety information and indications
for use. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national
health insurance. Additional information can be found
at www.neuronetics.com.
Media Contact:Chelsey MankoVault
Communications610-455-2778cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Mar 2023 to Mar 2024